Kalaris Therapeutics (NASDAQ:KLRS) Upgraded at Wall Street Zen

Key Points

• Kalaris Therapeutics has been upgraded to a "hold" rating by Wall Street Zen, amidst mixed ratings from other analysts, including a "strong-buy" from Raymond James and a "sell" rating from Weiss Ratings.
• The company reported a quarterly EPS of ($0.61), which missed analysts' consensus estimates by ($0.10).
• Kalaris Therapeutics' current stock price is $6.64, down $0.45 during recent trading, with a consensus price target set at $3.00.

Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) was upgraded by equities researchers at Wall Street Zen to a "hold" rating in a report released on Friday.

A number of other analysts have also recently commented on the stock. Raymond James Financial assumed coverage on shares of Kalaris Therapeutics in a research note on Tuesday, September 2nd. They issued a "strong-buy" rating for the company. Weiss Ratings reiterated a "sell (e)" rating on shares of Kalaris Therapeutics in a research note on Saturday, September 27th. Finally, Piper Sandler set a $3.00 price target on shares of Kalaris Therapeutics and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $3.00.

Kalaris Therapeutics Price Performance

KLRS stock traded down $0.45 during trading hours on Friday, reaching $6.64. The stock had a trading volume of 111,743 shares, compared to its average volume of 212,311. The company's 50-day moving average is $3.79. Kalaris Therapeutics has a fifty-two week low of $2.14 and a fifty-two week high of $24.15.

Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.10).

Institutional Trading of Kalaris Therapeutics

An institutional investor recently bought a new position in Kalaris Therapeutics stock. XTX Topco Ltd acquired a new position in Kalaris Therapeutics Inc. (NASDAQ:KLRS - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 24,234 shares of the company's stock, valued at approximately $65,000. XTX Topco Ltd owned approximately 0.13% of Kalaris Therapeutics as of its most recent SEC filing. 66.05% of the stock is currently owned by institutional investors.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.